Document is current
Any future updates will be listed below
-
Authors
Hughes, Daniel Johnathan http://orcid.org/0000-0003-2641-7632
Chand, Gitasha http://orcid.org/0000-0003-3565-3901
Johnson, Jessica
Bailey, Damion
Adamson, Kathryn
Goh, Vicky http://orcid.org/0000-0002-2321-8091
Cook, Gary J. R. http://orcid.org/0000-0002-8732-8134
-
Funding
Funding for this research was provided by:
Cancer Research UK (C1519/A28682)
Wellcome Trust (WT 203148/Z/16/Z)
- License Information
-
More Information
Article History
Received: 1 March 2023
Accepted: 19 May 2023
First Online: 31 May 2023
Declarations
:
: This study was conducted in accordance with the Declaration of Helsinki and underwent Research Ethics Committee and Health Research Authority, United Kingdom approval (IRAS 256684 and IRAS 290974). Written informed consent was provided by all participants.
: Not applicable.
: DJH has received honoraria/speaker fees from Pfizer, travel/accommodation grants from Bristol-Myers Squibb, Roche and NanoMab Technology, research funding via institute from NanoMab Technology, and is an executive committee member of the Association of Cancer Physicians (UK). GCh is a director and shareholder of NanoMab Technology (UK) Ltd. GJRC has research support via institute from NanoMab Technology, Theragnostics, Serac Healthcare and provides consultancy for GE Healthcare, NanoMab Technology, Amgen and Full-Life Technologies. All other authors report no competing interests.
